This book includes a plain text version that is designed for high accessibility. To use this version please follow this link.
11-01 :: December 2010 / January 2011


nanotimes


Companies Facts


se materials. Holographic information “inscribed” onto photopolymers by exposing them to laser beams can subsequently be made visible by various means.


Thanks to these outstanding properties, the films can also be used to create holographic optical elements (HOEs) that can reproduce the optical functions of lenses, mirrors and prisms in a thin film, or even combine them with one another.


Equally impressive: Sunscreen sprays and lotions can benefit in a variety of ways when formulated with the polyurethane dispersion Baycusan®


C 1000 from


Bayer MaterialScience. Although the film-forming polymer itself does not contain any UV-absorbing components, it can boost the sun protection factor (SPF) of a formulation. New test results confirm the varied benefits of Baycusan®


neither cosolvents nor preservatives. It has been confirmed, for example, that Baycusan®


of its common stock and warrants to purchase up to approximately 5.3 million additional shares of its common stock. Each unit, consisting of one share of common stock and a warrant to purchase 0.50 of a share of common stock, was sold for a purchase price of $1.70, a premium to the closing price on the prior full trading day before the securities purchase agreements were signed.


C 1000, which contains C 1000 not


only shows an SPF-boosting effect in formulations that include the UVB filters octocrylene and ethyl- hexyl triazone, but significantly increases the SPF of formulations based on broadband UV filters such as bis-ethylhexyloxyphenol methoxyphenyl triazine (BEMT) and benzophenone-3. Baycusan®


C 1000


also acts as a stabilizing raw material for oil-in-water (O/W) emulsions.. http://www.bayermaterialscience.com


B


ioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) closed a previously announced sale of an aggre-


gate of $18 million of securities in a registered direct offering. BioSante received net proceeds of appro- ximately $16.9 million after deducting placement agent fees and other offering expenses. BioSante sold an aggregate of approximately 10.6 million shares


The warrants to purchase additional shares are ex- ercisable immediately at an exercise price of $2.00 per share and will expire on December 29, 2015. All of the securities were offered pursuant to an effec- tive shelf registration statement. Proceeds from the transaction will be used for general corporate pur- poses, including BioSante’s LibiGel Phase III clinical study program. LibiGel remains the lead pharmaceu- tical product in the U.S. in active development for the treatment of hypoactive sexual desire disorder (HSDD) in menopausal women, and BioSante be- lieves that LibiGel has the potential to be the first product approved by the FDA for this common and unmet medical need.


Furthermore, BioSante Pharmaceuticals announced results of a survey of over 100 Obstetrician/Gyne- cologists and Primary Care Physicians regarding the need for an FDA-approved drug to treat a form of Female Sexual Dysfunction (FSD) known as Hypo- active Sexual Desire Disorder (HSDD). The multiple surveys, conducted independently for BioSante by Campbell Alliance Group, Inc., revealed sexual dys- function to be one of the most common complaints received in these doctors’ offices. The physicians described themselves as dissatisfied with the current lack of therapeutic options for HSDD, a loss of libido or sexual desire.


17


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95